Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis
Fiche publication
Date publication
mars 2017
Journal
The lancet. Gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F,
Lien Pubmed
Résumé
Findings from uncontrolled studies suggest that addition of pegylated interferon in patients with HBe antigen (HBeAg)-negative chronic hepatitis B receiving nucleos(t)ide analogues with undetectable plasma hepatitis B virus (HBV) DNA might increase HBs antigen (HBsAg) clearance. We aimed to assess this strategy.
Mots clés
Adolescent, Adult, Aged, Antiviral Agents, adverse effects, DNA, Viral, blood, Drug Administration Schedule, Female, Hepatitis B Surface Antigens, blood, Hepatitis B e Antigens, blood, Hepatitis B virus, genetics, Hepatitis B, Chronic, blood, Humans, Interferon-alpha, adverse effects, Male, Middle Aged, Nucleosides, adverse effects, Nucleotides, adverse effects, Patient Reported Outcome Measures, Polyethylene Glycols, adverse effects, Recombinant Proteins, adverse effects, Young Adult
Référence
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):177-188